Navigation Links
Viral Genetics' Researcher and Advisor Set to Share Award
Date:2/15/2011

://www.timeforlyme.org/">www.timeforlyme.org.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

www.viralgenetics.com Contact: Haig Keledjian, Viral GeneticsT: (626) 334-5310info@viralgenetics.com
'/>"/>

SOURCE Viral Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Viral Genetics Issues 2010 Year in Review, 2011 Outlook
2. Zacks Investment Research Initiates Coverage on Viral Genetics
3. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
4. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
5. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
6. Cocrystal Discovery Receives Awards for Its Novel Antiviral Drug Development Programs
7. AASLD Presidents Choice Lecture: The National Strategy for the Control of Viral Hepatitis and Liver Cancer
8. Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes
9. Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
10. Roche Receives FDA Approval for a Second-Generation Hepatitis C Viral Load Test
11. New American Therapeutics Acquires Antiviral Drug Denavir®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, ... company, today announced that the Food and Drug Administration ... provide comments on RCP,s Investigational New Drug ("IND") application ... trial in the US. Dr. Chris ... review and comments on our IND. When we receive ...
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
(Date:7/11/2014)... , July 11, 2014 ... at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished ... closed at 1,964.68, down 0.41%. The losses were broad based ... negative. The S&P 500 Health Care Sector Index ended the ... 2.75% in the last one month. Investor-Edge has initiated coverage ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
... May 20 Despite concerns from public health officials, influenza ... to a new analysis presented recently at the Academy of Managed Care ... (Prime), a thought leader in pharmacy benefit management. , ... For the study, researchers from Prime and ...
... Today, in a world first, Asda announces a commitment ... ,not for profit, basis potentially saving thousands of pounds for sufferers. ... UK and as part of Asda,s ,not for profit, commitment it ... cancer, is now available for 2,167.71 pounds Sterling compared ...
Cached Medicine Technology:New Prime Therapeutics Study Finds Antiviral Medications Were Not Hoarded During H1N1 Flu Season 2In a World First, Asda Announces 'Not for Profit' Price on All Cancer Treatment Drugs 2In a World First, Asda Announces 'Not for Profit' Price on All Cancer Treatment Drugs 3
(Date:7/11/2014)... 2014 The Europe Well Intervention Market report ... with analysis and revenue forecast. The well intervention services market ... in 2013 to $3.4 billion by 2018, at a CAGR ... TOC of the Europe Well Intervention Market report, to get ... a glimpse of the segmentation in the Europe well intervention ...
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... (HealthDay News) -- U.S. health officials have concluded that ... live anthrax during a safety mishap last month. ... officials have announced a moratorium on the transfer of ... In a report issued Friday, the CDC outlined ... a similar incident doesn,t occur again. Last month, as ...
(Date:7/11/2014)... CT (PRWEB) July 11, 2014 ... the nation’s only non-profit dedicated exclusively to cell ... that Joshua Corday has joined the organization as ... fundraising professional with deep experience securing gifts and ... served as Annual Giving Director for NewYork Presbyterian ...
(Date:7/11/2014)... July 11, 2014 Biostimulants are widely ... in turf and ornamentals. These also help turf and ... length of roots. Turf, ornamentals, and flowers appear healthy ... this usage has increased from the last few years. ... and ornamentals is Europe, with around 40% share in ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... 6 percent of U.S. hospital emergency departments are fully ... of novel H1N1 (swine) flu expected this winter, the ... In a joint policy statement published in Pediatrics ... Department," pediatric emergency medicine specialists and others provide recommendations ...
... Federal stimulus funding is helping a Kansas State University ... Their research is creating a clearer picture of a ... chronic diseases like cancer. Katsura Asano, K-State associate ... from the National Institutes of Health,s National Institute of ...
... so-called junk DNA to be cut and pasted within genetic ... therapies. The study by researchers at the University of ... in which shifted genes have a significant effect on the ... antibody genes can enable the immune system to target infection ...
... NEW YORK, Sept. 21 Within the first three seconds ... in many first encounters, from the first day of school to the ... help you exude confidence, so follow these helpful tips to get yourself ... go to: http://www.prnewswire.com/mnr/crest/39172/ , , ...
... INDIANAPOLIS, Sept. 21 Eli Lilly and Company ... on the Human Rights Campaign,s (HRC) Corporate Equality Index for 2010. ... the Best Places to Work for Lesbian, Gay, Bisexual, and Transgender (LGBT) ... organization,s efforts related to creating an equitable environment for lesbian, gay, bisexual, ...
... , , ABBOTT PARK, Ill., Sept. 21 ... from the U.S. Food and Drug Administration (FDA) for its ABBOTT PRISM ... HIV-1/HIV-2. This test can be used by laboratory professionals to screen ... type 1 Groups M and O (anti-HIV-1) and type 2 (anti-HIV-2), and ...
Cached Medicine News:Health News:Photos: Fall's First Impressions 2Health News:Lilly Receives 100 Percent Rating on Corporate Equality Index Survey 2Health News:Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2 2Health News:Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2 3
... In the specialty areas of ... intensive care work, it is ... your practice. Alokas motorized TEE ... and Tissue Harmonic Echo technology ...
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... The 5548 is our High Penetration ... frequencies ranging from 3 to 8 MHz. ... transducer, offering Pure Harmonic Detection with 4 ... superficial or deeper vessels. The high color ...
... The UST-MC11-8731 is a perfect alternative ... are used to seeing more of a ... of the transducer in the hand., This ... shaped convex intraoperative transducer. The UST-MC11-8731 nestles ...
Medicine Products: